Kenzie L Preston

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7469689/publications.pdf

Version: 2024-02-01

45317 31976 9,519 175 53 90 citations h-index g-index papers 179 179 179 6884 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Trajectories of craving during medication-assisted treatment for opioid-use disorder: Subtyping for early identification of higher risk. Drug and Alcohol Dependence, 2022, 233, 109362.	3.2	4
2	Being at work improves stress, craving, and mood for people with opioid use disorder: Ecological momentary assessment during a randomized trial of experimental employment in a contingency-management-based therapeutic workplace. Behaviour Research and Therapy, 2022, 152, 104071.	3.1	3
3	Intra-individual variability and stability of affect and craving among individuals receiving medication treatment for opioid use disorder. Neuropsychopharmacology, 2022, 47, 1836-1843.	5.4	3
4	Craving mediates the association between momentary pain and illicit opioid use during treatment for opioidâ€use disorder: an ecological momentary assessment study. Addiction, 2021, 116, 1794-1804.	3.3	12
5	Reward Responsiveness in Patients with Opioid Use Disorder on Opioid Agonist Treatment: Role of Comorbid Chronic Pain. Pain Medicine, 2021, 22, 2019-2027.	1.9	3
6	Beyond abstinence and relapse II: momentary relationships between stress, craving, and lapse within clusters of patients with similar patterns of drug use. Psychopharmacology, 2021, 238, 1513-1529.	3.1	17
7	An Examination of the Feasibility of Detecting Cocaine Use Using Smartwatches. Frontiers in Psychiatry, 2021, 12, 674691.	2.6	3
8	I feel good? Anhedonia might not mean "without pleasure―for people treated for opioid use disorder Journal of Abnormal Psychology, 2021, 130, 537-549.	1.9	3
9	Exploring the Relationship Between Substance Use and Allostatic Load in a Treatment/Research Cohort and in a US Probability Sample (NHANES 2009–2016). Frontiers in Psychiatry, 2021, 12, 630195.	2.6	O
10	Longitudinal patterns of momentary stress during outpatient opioid agonist treatment: A growth-mixture-model approach to classifying patients. Drug and Alcohol Dependence, 2021, 226, 108884.	3.2	6
11	Quality of life during a randomized trial of a therapeutic-workplace intervention for opioid use disorder: Web-based mobile assessments reveal effects of drug abstinence and access to paid work. , 2021, 1, 100011.		3
12	Beyond abstinence and relapse: cluster analysis of drug-use patterns during treatment as an outcome measure for clinical trials. Psychopharmacology, 2020, 237, 3369-3381.	3.1	16
13	Prediction of stress and drug craving ninety minutes in the future with passively collected GPS data. Npj Digital Medicine, 2020, 3, 26.	10.9	40
14	Uncertainties in the geographic context of health behaviors: a study of substance users' exposure to psychosocial stress using GPS data. International Journal of Geographical Information Science, 2019, 33, 1176-1195.	4.8	54
15	Defining and Predicting Opioid and Cocaine Treatment Response. Substance Use and Misuse, 2019, 54, 2134-2143.	1.4	3
16	Stress, craving and mood as predictors of early dropout from opioid agonist therapy. Drug and Alcohol Dependence, 2019, 202, 200-208.	3.2	68
17	Towards detecting cocaine use using smartwatches in the NIDA clinical trials network: Design, rationale, and methodology. Contemporary Clinical Trials Communications, 2019, 15, 100392.	1.1	13
18	Craving and opioid use disorder: A scoping review. Drug and Alcohol Dependence, 2019, 205, 107639.	3.2	31

#	Article	IF	CITATIONS
19	Sleep reductions associated with illicit opioid use and clinic-hour changes during opioid agonist treatment for opioid dependence: Measurement by electronic diary and actigraphy. Journal of Substance Abuse Treatment, 2019, 106, 43-57.	2.8	25
20	The chippers, the quitters, and the highly symptomatic: A 12-month longitudinal study of DSM-5 opioidand cocaine-use problems in a community sample. Addictive Behaviors, 2019, 96, 183-191.	3.0	11
21	Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African–Americans with opioidÂuse disorder. Pharmacogenomics Journal, 2019, 19, 260-268.	2.0	17
22	Sex differences in daily life stress and craving in opioid-dependent patients. American Journal of Drug and Alcohol Abuse, 2018, 44, 512-523.	2.1	45
23	Using ecological momentary assessment to examine the relationship between craving and affect with opioid use in a clinical trial of clonidine as an adjunct medication to buprenorphine treatment. American Journal of Drug and Alcohol Abuse, 2018, 44, 502-511.	2.1	21
24	Combining ecological momentary assessment with objective, ambulatory measures of behavior and physiology in substance-use research. Addictive Behaviors, 2018, 83, 5-17.	3.0	59
25	Exacerbated Craving in the Presence of Stress and Drug Cues in Drug-Dependent Patients. Neuropsychopharmacology, 2018, 43, 859-867.	5.4	69
26	End-of-day reports of daily hassles and stress in men and women with opioid-use disorder: Relationship to momentary reports of opioid and cocaine use and stress. Drug and Alcohol Dependence, 2018, 193, 21-28.	3.2	31
27	Before and after: craving, mood, and background stress in the hours surrounding drug use and stressful events in patients with opioid-use disorder. Psychopharmacology, 2018, 235, 2713-2723.	3.1	52
28	Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder. Psychopharmacology, 2018, 235, 2957-2966.	3.1	13
29	Context and craving during stressful events in the daily lives of drug-dependent patients. Psychopharmacology, 2017, 234, 2631-2642.	3.1	49
30	Clonidine Increases the Likelihood That Abstinence Can Withstand Unstructured Time in Buprenorphine-maintained Outpatients. Journal of Addiction Medicine, 2017, 11, 454-460.	2.6	10
31	mDebugger: Assessing and Diagnosing the Fidelity and Yield of Mobile Sensor Data., 2017,, 121-143.		6
32	Cognitiveâ€behavioural therapy for heroin and cocaine use: Ecological momentary assessment of homework simplification and compliance. Psychology and Psychotherapy: Theory, Research and Practice, 2016, 89, 276-293.	2.5	13
33	Real-time assessment of alcohol drinking and drug use in opioid-dependent polydrug users. Behavioural Pharmacology, 2016, 27, 579-584.	1.7	25
34	Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Drug and Alcohol Dependence, 2016, 158, 1-7.	3.2	49
35	Some of the people, some of the time: field evidence for associations and dissociations between stress and drug use. Psychopharmacology, 2015, 232, 3529-3537.	3.1	40
36	Tailored, Interactive Text Messages for Enhancing Weight Loss Among African American Adults: The TRIMM Randomized Controlled Trial. American Journal of Medicine, 2015, 128, 896-904.	1.5	64

#	Article	IF	CITATIONS
37	Continuous in-the-field measurement of heart rate: Correlates of drug use, craving, stress, and mood in polydrug users. Drug and Alcohol Dependence, 2015, 151, 159-166.	3.2	46
38	Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment. American Journal of Psychiatry, 2015, 172, 760-767.	7.2	80
39	No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper. American Journal on Addictions, 2015, 24, 323-328.	1.4	30
40	Are we there yet?. , 2014, 2014, 479-488.		49
41	Real-time tracking of neighborhood surroundings and mood in urban drug misusers: Application of a new method to study behavior in its geographical context. Drug and Alcohol Dependence, 2014, 134, 22-29.	3.2	113
42	Psychostimulant addiction treatment. Neuropharmacology, 2014, 87, 150-160.	4.1	67
43	Substance use and hepatitis C: An ecological momentary assessment study Health Psychology, 2014, 33, 710-719.	1.6	11
44	Identifying Drug (Cocaine) Intake Events from Acute Physiological Response in the Presence of Free-living Physical Activity., 2014, 2014, 71-82.		25
45	Sex differences in cocaine/heroin users: Drug-use triggers and craving in daily life. Drug and Alcohol Dependence, 2013, 132, 29-37.	3.2	122
46	A randomized investigation of methadone doses at or over 100mg/day, combined with contingency management. Drug and Alcohol Dependence, 2013, 130, 77-84.	3.2	11
47	Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. Drug and Alcohol Dependence, 2013, 131, 258-262.	3.2	39
48	Daily temporal patterns of heroin and cocaine use and craving: Relationship with business hours regardless of actual employment status. Addictive Behaviors, 2013, 38, 2485-2491.	3.0	17
49	Smartphone Delivery of Mobile HIV Risk Reduction Education. AIDS Research and Treatment, 2013, 2013, 1-9.	0.7	17
50	Buprenorphine in Maintenance Therapy., 2013,, 139-162.		3
51	TGI Monday?: Drugâ€Dependent Outpatients Report Lower Stress and More Happiness at Work than Elsewhere. American Journal on Addictions, 2012, 21, 189-198.	1.4	22
52	Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: Dose–effects and time-course. Drug and Alcohol Dependence, 2012, 123, 57-65.	3.2	39
53	Cardiac Complications of Unwitting Co-injection of Quinine/Quinidine with Heroin in an Intravenous Drug User. Journal of General Internal Medicine, 2012, 27, 1722-1725.	2.6	24
54	Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use endâ€points in clinical trials. Addiction, 2012, 107, 694-708.	3.3	184

#	Article	IF	CITATIONS
55	Incubation of Cue-Induced Cigarette Craving During Abstinence in Human Smokers. Biological Psychiatry, 2011, 69, 708-711.	1.3	199
56	Cigarette smoking and short-term addiction treatment outcome. Drug and Alcohol Dependence, 2011, 115, 161-166.	3.2	13
57	Stress in the daily lives of cocaine and heroin users: relationship to mood, craving, relapse triggers, and cocaine use. Psychopharmacology, 2011, 218, 29-37.	3.1	150
58	Clonidine blocks stress-induced craving in cocaine users. Psychopharmacology, 2011, 218, 83-88.	3.1	72
59	Daily life hour by hour, with and without cocaine: an ecological momentary assessment study. Psychopharmacology, 2010, 211, 223-232.	3.1	56
60	A Focus-Group Study on Spirituality and Substance-User Treatment. Substance Use and Misuse, 2010, 45, 134-153.	1.4	28
61	Brain Mu-Opioid Receptor Binding Predicts Treatment Outcome in Cocaine-Abusing Outpatients. Biological Psychiatry, 2010, 68, 697-703.	1.3	54
62	Tobacco, cocaine, and heroin: Craving and use during daily life. Addictive Behaviors, 2010, 35, 318-324.	3.0	105
63	PGIS: Electronic diary data integration with GPS data initial application in substance-abuse patients. , $2010, \ldots$		7
64	Addiction and emotion: Theories, assessment techniques, and treatment implications, 2010, , 259-280.		2
65	Real-Time Electronic Diary Reports of Cue Exposure and Mood in the Hours Before Cocaine and Heroin Craving and Use. Archives of General Psychiatry, 2009, 66, 88.	12.3	256
66	Electrocardiographic Effects of Lofexidine and Methadone Coadministration: Secondary Findings from a Safety Study. Pharmacotherapy, 2009, 29, 495-502.	2.6	20
67	Cocaine craving and use during daily life. Psychopharmacology, 2009, 207, 291-301.	3.1	103
68	Automation in an addiction treatment research clinic: Computerised contingency management, ecological momentary assessment and a protocol workflow system. Drug and Alcohol Review, 2009, 28, 3-11.	2.1	11
69	Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. Drug and Alcohol Dependence, 2009, 101, 92-100.	3.2	58
70	Marriage and relationship closeness as predictors of cocaine and heroin use. Addictive Behaviors, 2009, 34, 258-263.	3.0	90
71	Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. Journal of Substance Abuse Treatment, 2008, 35, 78-86.	2.8	27
72	Self-report of illicit benzodiazepine use on the Addiction Severity Index predicts treatment outcome. Drug and Alcohol Dependence, 2008, 97, 150-157.	3.2	42

#	Article	IF	CITATIONS
73	Contingency management reduces injection-related HIV risk behaviors in heroin and cocaine using outpatients. Addictive Behaviors, 2008, 33, 593-604.	3.0	23
74	RANDOMIZED TRIAL COMPARING TWO TREATMENT STRATEGIES USING PRIZEâ€BASED REINFORCEMENT OF ABSTINENCE IN COCAINE AND OPIATE USERS. Journal of Applied Behavior Analysis, 2008, 41, 551-563.	2.7	21
75	EFFECT OF REINFORCEMENT PROBABILITY AND PRIZE SIZE ON COCAINE AND HEROIN ABSTINENCE IN PRIZEâ€BASED CONTINGENCY MANAGEMENT. Journal of Applied Behavior Analysis, 2008, 41, 539-549.	2.7	18
76	Spiritual/Religious Experiences and In-Treatment Outcome in an Inner-City Program for Heroin and Cocaine Dependence. Journal of Psychoactive Drugs, 2007, 39, 41-49.	1.7	32
77	Randomized trial of prize-based reinforcement density for simultaneous abstinence from cocaine and heroin Journal of Consulting and Clinical Psychology, 2007, 75, 765-774.	2.0	28
78	Nonreporting of cannabis use: Predictors and relationship to treatment outcome in methadone maintained patients. Addictive Behaviors, 2007, 32, 938-949.	3.0	16
79	Psychosocial functioning and cocaine use during treatment: Strength of relationship depends on type of urine-testing method. Drug and Alcohol Dependence, 2007, 91, 169-177.	3.2	16
80	Computerized Contingency Management for Motivating Behavior Change: Automated Tracking and Dynamic Reward Reinforcement Management. Proceedings of the IEEE Symposium on Computer-Based Medical Systems, 2007, , .	0.0	3
81	Hemodynamic and Cognitive Effects of Lofexidine and Methadone Coadministration: A Pilot Study. Pharmacotherapy, 2007, 27, 1111-1119.	2.6	12
82	Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology, 2007, 194, 505-515.	3.1	144
83	Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence. Addictive Behaviors, 2006, 31, 868-879.	3.0	46
84	The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. American Heart Journal, 2006, 151, 754.e1-754.e5.	2.7	64
85	Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: Lessons from tramadol. Biological Psychology, 2006, 73, 90-99.	2.2	117
86	Heroin and cocaine craving and use during treatment: Measurement validation and potential relationships. Journal of Substance Abuse Treatment, 2006, 31, 355-364.	2.8	83
87	Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans Experimental and Clinical Psychopharmacology, 2006, 14, 109-120.	1.8	18
88	Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology, 2006, 189, 1-16.	3.1	563
89	Determination of total and free concentrations of the enantiomers of methadone and its metabolite (2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine) in human plasma by enantioselective liquid chromatography with mass spectrometric detection. Journal of Chromatography A, 2005, 1073, 237-248.	3.7	38
90	Menstrual cycle length during methadone maintenance. Addiction, 2005, 100, 829-836.	3.3	43

#	Article	IF	Citations
91	Influence of psychotherapy attendance on buprenorphine treatment outcome. Journal of Substance Abuse Treatment, 2005, 28, 247-254.	2.8	33
92	Adverse events among patients in a behavioral treatment trial for heroin and cocaine dependence: Effects of age, race, and gender. Drug and Alcohol Dependence, 2005, 80, 45-51.	3.2	11
93	A high-level specification for adaptive ecological momentary assessment: real-time assessment of drug craving, use and abstinence. AMIA Annual Symposium proceedings, 2005, , 455-9.	0.2	3
94	QT interval increased after single dose of lofexidine. BMJ: British Medical Journal, 2004, 329, 1075.	2.3	11
95	A laboratory study of hydromorphone and cyclazocine on smoking behavior in residential polydrug users. Pharmacology Biochemistry and Behavior, 2004, 77, 711-715.	2.9	7
96	Gender Differences in Indices of Opioid Dependency and Medical Comorbidity in a Population of Hospitalized HIV-Infected African-Americans. American Journal on Addictions, 2004, 13, 281-291.	1.4	2
97	Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clinical Pharmacology and Therapeutics, 2004, 75, 34-48.	4.7	133
98	Effects of High-Dose Intravenous Buprenorphine in Experienced Opioid Abusers. Journal of Clinical Psychopharmacology, 2004, 24, 479-487.	1.4	43
99	Cyclazocine: comparison to hydromorphone and interaction with cocaine. Behavioural Pharmacology, 2004, 15, 91-102.	1.7	17
100	The reinstatement model and relapse prevention: a clinical perspective. Psychopharmacology, 2003, 168, 31-41.	3.1	181
101	Quantitative determination of the enantiomers of methadone and its metabolite (EDDP) in human saliva by enantioselective liquid chromatography with mass spectrometric detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 796, 355-370.	2.3	33
102	Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction, 2003, 98, 269-279.	3.3	81
103	Cannabis use and treatment outcome in methadone maintenance. Addiction, 2003, 98, 1321-1322.	3.3	5
104	Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug and Alcohol Dependence, 2003, 69, 263-272.	3.2	61
105	Methadone and Metabolite Urine Concentrations in Patients Maintained on Methadone. Journal of Analytical Toxicology, 2003, 27, 332-341.	2.8	34
106	Methadone Treatment Induces Attenuation of Cerebrovascular Deficits Associated with the Prolonged Abuse of Cocaine and Heroin. Neuropsychopharmacology, 2003, 28, 562-568.	5.4	13
107	Do noncontingent vouchers increase drug use?. Experimental and Clinical Psychopharmacology, 2003, 11, 195-201.	1.8	6
108	Cognitive-behavioral therapy plus contingency management for cocaine use: Findings during treatment and across 12-month follow-up Psychology of Addictive Behaviors, 2003, 17, 73-82.	2.1	134

#	Article	lF	Citations
109	Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence. American Journal of Drug and Alcohol Abuse, 2002, 28, 189-196.	2.1	16
110	Urinary Elimination of Cocaine Metabolites in Chronic Cocaine Users during Cessation. Journal of Analytical Toxicology, 2002, 26, 393-400.	2.8	71
111	Toxicologic Aspects of Heroin Substitution Treatment. Therapeutic Drug Monitoring, 2002, 24, 193-198.	2.0	23
112	A dose response study of cognitive behavioral therapy in cocaine abusers. Journal of Substance Abuse Treatment, 2002, 23, 191-197.	2.8	27
113	Abstinence reinforcement maintenance contingency and one-year follow-up. Drug and Alcohol Dependence, 2002, 67, 125-137.	3.2	47
114	Family history influence on drug abuse severity and treatment outcome. Drug and Alcohol Dependence, 2001, 61, 261-270.	3.2	26
115	Shaping cocaine abstinence by successive approximation Journal of Consulting and Clinical Psychology, 2001, 69, 643-654.	2.0	55
116	Blockade of Effects of Smoked Marijuana by the CB1-Selective Cannabinoid Receptor Antagonist SR141716. Archives of General Psychiatry, 2001, 58, 322.	12.3	437
117	Shaping cocaine abstinence by successive approximation Journal of Consulting and Clinical Psychology, 2001, 69, 643-654.	2.0	29
118	Methadone Dose Increase and Abstinence Reinforcement for Treatment of Continued Heroin Use During Methadone Maintenance. Archives of General Psychiatry, 2000, 57, 395.	12.3	126
119	Pathological Gambling Among Cocaine-Dependent Outpatients. American Journal of Psychiatry, 2000, 157, 1127-1133.	7.2	107
120	The brief abstinence test: voucher-based reinforcement of cocaine abstinence. Drug and Alcohol Dependence, 2000, 58, 205-212.	3.2	44
121	Monitoring Cocaine Use in Substance-Abuse-Treatment Patients by Sweat and Urine Testing. Journal of Analytical Toxicology, 1999, 23, 313-322.	2.8	60
122	Improvement in naltrexone treatment compliance with contingency management. Drug and Alcohol Dependence, 1999, 54, 127-135.	3.2	160
123	Naltrexone shortened opioid detoxification with buprenorphine. Drug and Alcohol Dependence, 1999, 56, 181-190.	3.2	77
124	Low-dose oral cocaine in humans: acquisition of discrimination and time-course of effects. Behavioural Pharmacology, 1999, 10, 531-542.	1.7	10
125	Occurrence of Cocaine in Urine of Substance-Abuse Treatment Patients. Journal of Analytical Toxicology, 1998, 22, 580-586.	2.8	17
126	Site of Opioid Action in the Human Brain: Mu and Kappa Agonists' Subjective and Cerebral Blood Flow Effects. American Journal of Psychiatry, 1998, 155, 470-473.	7.2	137

#	Article	IF	CITATIONS
127	Cocaine use early in treatment predicts outcome in a behavioral treatment program Journal of Consulting and Clinical Psychology, 1998, 66, 691-696.	2.0	105
128	Broad beneficial effects of cocaine abstinence reinforcement among methadone patients Journal of Consulting and Clinical Psychology, 1998, 66, 811-824.	2.0	169
129	The influence of an instruction on the stimulus effects of drugs in humans Experimental and Clinical Psychopharmacology, 1998, 6, 427-432.	1.8	4
130	Cocaine effects on digital blood flow and diffusing capacity for carbon monoxide among chronic cocaine users. American Journal of Medicine, 1997, 102, 232-238.	1.5	9
131	Assessment of cocaine use with quantitative urinalysis and estimation of new uses. Addiction, 1997, 92, 717-727.	3.3	94
132	The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology, 1997, 129, 329-338.	3.1	51
133	Bridging the information gap: assimilating preclinical and clinical findings. Psychopharmacology, 1997, 130, 1-1.	3.1	0
134	Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects. Psychopharmacology, 1997, 130, 14-27.	3.1	57
135	Rapid liquid–liquid extraction of cocaine from urine for gas chromatographic–mass spectrometric analysis. Biomedical Applications, 1997, 692, 61-65.	1.7	15
136	Assessment of cocaine use with quantitative urinalysis and estimation of new uses. Addiction, 1997, 92, 717-728.	3.3	0
137	Safety and Efficacy of Bupropion Combined With Bromocriptine for Treatment of Cocaine Dependence. American Journal on Addictions, 1996, 5, 69-75.	1.4	8
138	Increasing opiate abstinence through voucher-based reinforcement therapy. Drug and Alcohol Dependence, 1996, 41, 157-165.	3.2	143
139	Absorption rate of methylxanthines following capsules, cola and chocolate. European Journal of Clinical Pharmacology, 1996, 51, 319-325.	1.9	90
140	Opioid antagonist effects of dezocine in opioid-dependent humans*. Clinical Pharmacology and Therapeutics, 1996, 60, 206-217.	4.7	17
141	5-HT3 receptor antagonism and psychoactivity. Journal of Psychopharmacology, 1996, 10, 182-187.	4.0	0
142	Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology, 1995, 119, 268-276.	3.1	118
143	A model for pharmacological researchâ€"treatment of cocaine dependence. Journal of Substance Abuse Treatment, 1995, 12, 415-421.	2.8	3
144	Buprenorphine for human immunovirus-positive opiate-dependent patients. Biological Psychiatry, 1995, 38, 135-136.	1.3	2

#	Article	IF	CITATION
145	Buprenorphine Reduces Cerebral Glucose Metabolism in Polydrug Abusers. Neuropsychopharmacology, 1994, 10, 157-170.	5.4	25
146	Discriminative stimulus and subjective effects of theobromine and caffeine in humans. Psychopharmacology, 1994, 115, 1-8.	3.1	103
147	Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics, 1994, 55, 569-580.	4.7	670
148	Psychopharmacology and abuse potential of transnasal butorphanol. Drug and Alcohol Dependence, 1994, 35, 159-167.	3.2	12
149	Fluoxetine Alters the Effects of Intravenous Cocaine in Humans. Journal of Clinical Psychopharmacology, 1994, 14, 396???407.	1.4	81
150	Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug and Alcohol Dependence, 1992, 30, 263-274.	3.2	50
151	Supersensitivity to Naloxone following acute morphine pretreatment in humans: behavioral, hormonal and physiological effects. Drug and Alcohol Dependence, 1992, 30, 13-26.	3.2	14
152	Psychoactivity and abuse potential of sumatriptan. Clinical Pharmacology and Therapeutics, 1992, 52, 635-642.	4.7	35
153	Abuse liability studies of opioid agonist-antagonists in humans. Drug and Alcohol Dependence, 1991, 28, 49-82.	3.2	84
154	Abuse potential and pharmacological comparison of tramadol and morphine. Drug and Alcohol Dependence, 1991, 27, 7-17.	3.2	216
155	Evaluation of the abuse potential of the novel analgesic flupirtine maleate. Drug and Alcohol Dependence, 1991, 27, 101-113.	3.2	7
156	Drug discrimination methods in human drug abuse liability evaluation. Addiction, 1991, 86, 1587-1594.	3.3	28
157	Drug abstinence effects: opioids. Addiction, 1991, 86, 1641-1646.	3.3	6
158	Discrimination of butorphanol and nalbuphine in opioid-dependent humans. Pharmacology Biochemistry and Behavior, 1990, 37, 511-522.	2.9	35
159	Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug and Alcohol Dependence, 1990, 25, 27-34.	3.2	68
160	Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology, 1988, 94, 484-490.	3.1	81
161	Diazepam and methadone blood levels following concurrent administration of diazepam and methadone. Drug and Alcohol Dependence, 1986, 18, 195-202.	3.2	39
162	Evaluation of mixtures of morphine and d-amphetamine for subjective and physiological effects. Drug and Alcohol Dependence, 1986, 17, 1-13.	3.2	38

#	Article	IF	Citations
163	Comparison of intravenously administered methadone, morphine and heroin. Drug and Alcohol Dependence, 1986, 17, 301-310.	3.2	49
164	Evaluation of tilidine for morphine-like subjective effects and euphoria. Drug and Alcohol Dependence, 1986, 18, 273-292.	3.2	22
165	Self-administration of clonidine, oxazepam, and hydromorphone by patients undergoing methadone detoxification. Clinical Pharmacology and Therapeutics, 1985, 38, 219-227.	4.7	20
166	Assessment of dezocine for morphine-like subjective effects and miosis. Clinical Pharmacology and Therapeutics, 1985, 38, 544-548.	4.7	20
167	Methamphetamine, physostigmine, atropine and mecamylamine: Effects on force lever performance. Pharmacology Biochemistry and Behavior, 1985, 23, 781-788.	2.9	13
168	Pharmacological Advances in Addiction Treatment. Substance Use and Misuse, 1985, 20, 845-867.	0.6	32
169	Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain. Brain Research, 1985, 338, 243-248.	2.2	83
170	Effects of methamphetamine on atropine-induced conditioned gustatory avoidance. Pharmacology Biochemistry and Behavior, 1984, 20, 601-607.	2.9	1
171	Diazepam and methadone interactions in methadone maintenance. Clinical Pharmacology and Therapeutics, 1984, 36, 534-541.	4.7	70
172	A comparison of the central and peripheral effects of atropine on force lever performance. Pharmacology Biochemistry and Behavior, 1982, 16, 423-427.	2.9	4
173	Conditioned gustatory avoidance induced by three cholinergic agents. Pharmacology Biochemistry and Behavior, 1981, 15, 827-828.	2.9	9
174	The aversive stimulus properties of repeated infusions of cocaine. Pharmacology Biochemistry and Behavior, 1981, 15, 71-74.	2.9	15
175	Phencyclidine-induced stereotyped behavior in monkeys: Antagonism by pimozide. European Journal of Pharmacology, 1978, 52, 379-384.	3.5	64